Nuventra founder inks deal for new venture that could be worth as much as $49 million
A Research Triangle Park-based virtual drug development company 1st Order Pharmaceuticals (1OP) has inked a deal with Canada ’s Xenon Pharmaceuticals (Nasdaq: XENE) that could be worth as much as $49 million.
1OP was founded in 2013 by Christopher Crean, former North American head of Clinical Pharmacology and Pharmacokinetics at Valeant Pharmaceuticals (NYSE: VRX), and Dr. Geoffrey Banks, founder and CEO of fast-growin g, Durham-based drug development consultancy Nuventra Pharma Sciences. Crean…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Biotechnology | Consultancies | Drugs & Pharmacology | Health Management | Pharmaceuticals